title: Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: long-term benefit of rituximab.
abstract: Diffuse alveolar haemorrhage (DAH) is an uncommon complication of systemic lupus erythematosus (SLE), and recurrences of DAH with remission periods are unusual. We describe a young woman with cachexia as the initial manifestation of SLE who presented posterior reversible encephalopathy syndrome (PRES), intestinal vasculitis and four episodes of DAH even though she was receiving combined immune suppressive therapy. After treatment with rituximab (RTX) the patient has not presented further episodes of DAH.
authors.affiliation: Regional Unit of Rheumatology and Osteoporosis, Central Hospital "Dr. Ignacio Morones Prieto" and Faculty of Medicine, Universidad Autónoma de San Luis Potosí, México.
authors.forename: M U
authors.initials: MU
authors.lastname: Martínez-Martínez
authors.forename: C
authors.initials: C
authors.lastname: Abud-Mendoza
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D002100:Cachexia / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000150:complications* / Q000628:therapy*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D054038:Posterior Leukoencephalopathy Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D011650:Pulmonary Alveoli; D012008:Recurrence; D000069283:Rituximab; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab